Lupin Ltd. (LUPIN) 52 Week Low Streak: Why The Stock Is Still Near Its One-Year Low

Lupin 52 Week Low Streak has now extended to its second straight session, with the stock continuing to trade within 2% of its 52-week low. Across the streak, the share price has moved down 1.92%. At 9:52 AM IST, Lupin Ltd. last traded at Rs 1,916.15 after touching a low of Rs 1,897.25, and the latest Univest data confirms the repeated near-low pattern but does not establish a company-specific cause for the continued decline.

From the previous close of Rs 1957, the stock opened at Rs 1,944 and also touched a high of Rs 1,944 in early trade before slipping lower again. With a market capitalisation of Rs 89,343.03 crore, the repeated-low pattern matters because it points to persistent weakness across multiple sessions rather than a one-day drift. For readers tracking Lupin 52 Week Low Streak, the question is less about a single print and more about whether the broader share price remains under pressure near the yearly low.

Lupin 52 Week Low Streak: Consecutive Low Analysis

Metric	Value
Current Price	Rs 1,916.15
Previous Close	Rs 1,957
Today's Move	Rs -40.85 (-2.09%)
Open	Rs 1,944
High	Rs 1,944
Low	Rs 1,897.25
Market Capitalisation	Rs 89,343.03 crore

Lupin Ltd. (LUPIN) traded at Rs 1,916.15 versus the previous close of Rs 1,957, a fall of 2.09%. The stock opened at Rs 1,944, reached a high of Rs 1,944, touched a low of Rs 1,897.25.

At 9:52 AM IST, Lupin Ltd. was trading at Rs 1,916.15, down Rs 40.85 or 2.09% from the previous close of Rs 1,957. The stock opened at Rs 1,944 and also touched a high of Rs 1944, which shows that early trade stayed subdued before the price moved lower. The day’s low so far is Rs 1,897.25, placing the stock close to the lower end of the intraday range and keeping the Lupin share price near its yearly low zone.

The current level is below the opening price and below the previous close, which keeps the intraday tone weak. For readers following Lupin share price today, the key point is that the move is not just a single-session dip: it is part of Lupin 52 Week Low Streak, now in a second straight session. The market capitalisation of Rs 89,343.03 crore places the company among a large listed healthcare name, but size alone does not prevent repeated price weakness. The current price is trading much closer to the day’s low than the day’s high, which reinforces the near-52-week-low pattern.

What The Repeated 52-Week Lows Show

Lupin 52 Week Low Streak is the main signal to watch here. The stock has remained within 2% of its 52-week low for two consecutive trading sessions, and the cumulative decline across that stretch stands at 1.92%. That is more useful than looking only at today’s change, because it shows that the weakness has persisted across multiple sessions rather than appearing in isolation. The latest Univest data confirms the pattern, but it does not identify a company-specific trigger for why the stock has continued to trade so close to its one-year low.

For market readers, this repeated pattern usually means the stock is staying under pressure relative to its recent trading history. It also means that the focus shifts from a one-day move to the broader direction of the share price over the streak. Lupin share price has therefore become a watchlist stock not because of a single sharp fall, but because the stock has been unable to move far away from the lower end of its 52-week band.

Lupin Ltd. (LUPIN) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 89,343.03 crore
P/E Ratio	16.19x
P/B Ratio	3.76x
ROE	27.11%
ROCE	28.86%
EPS	Rs 120.9
Book Value Per Share	Rs 520.48
Dividend Yield	0.92%

Lupin Ltd. (LUPIN) fundamental metrics show P/E 16.19x, P/B 3.76x, ROE 27.11%, ROCE 28.86%. These figures provide context only and are not a buy or sell signal.

Lupin Ltd. has a market capitalisation of Rs 89,343.03 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 16.19x, P/B at 3.76x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 27.11% and ROCE of 28.86%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 120.9, book value per share of Rs 520.48, dividend yield of 0.92%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 27.02x, median ROE of 11.23%, median ROCE of 13.17%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	16.19x
Benchmark Median P/E	27.02x
Benchmark Average P/E	38.89x
Benchmark P/E Range	0x to 616.23x
Company P/B Ratio	3.76x
Benchmark Median P/B	2.67x
Company ROE	27.11%
Benchmark Median ROE	11.23%
Company ROCE	28.86%
Benchmark Median ROCE	13.17%
Company Market Capitalisation	Rs 89,343.03 crore
Benchmark Median Market Cap	Rs 768.75 crore

Lupin Ltd. (LUPIN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Lupin Ltd. (LUPIN) has a P/E ratio of 16.19x, which is below the benchmark median of 27.02x, a difference of -40.08%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Lupin Ltd. (LUPIN) has a ROE of 27.11%, which is above the benchmark median of 11.23%, a difference of +141.41%. Lupin Ltd. (LUPIN) has a ROCE of 28.86%, which is above the benchmark median of 13.17%, a difference of +119.13%.

Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Aurobindo Pharma Ltd.	AUROPHARMA	92,923.53	24.43	2.33	9.93	12.76
Mankind Pharma Ltd.	MANKIND	93,013.62	46.12	5.6	12.69	13.24
Dr. Reddy's Laboratories Ltd.	DRREDDY	1,03,667.29	32.06	2.71	11.69	13.75
Cipla Ltd.	CIPLA	1,07,527.58	31.49	3.02	11.83	16
Zydus Lifesciences Ltd.	ZYDUSLIFE	1,11,022.18	24.7	4.13	19.69	21.39

Lupin Ltd. (LUPIN) has a P/E ratio of 16.19x compared with the displayed peer median of 31.49x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 27.11% compares with a peer median of 11.83% across the companies shown in the table. ROCE stood at 28.86% versus the displayed peer median of 13.75%, providing a capital-efficiency comparison. Lupin Ltd. (LUPIN) has a market capitalisation of Rs 89,343.03 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Why Investors Are Watching

• The stock is in Lupin 52 Week Low Streak territory for a second straight session, which keeps the repeated weakness in focus.
• The cumulative move across the streak is -1.92%, which is more informative than a one-day change alone.
• Lupin share price is trading near the lower end of the intraday range, keeping attention on the yearly low zone.
• The P/E of 16.19 is below the healthcare industry median, while ROE and ROCE remain well above the sector median.
• There is no confirmed company-specific cause in the latest Univest data, so investors are watching the pattern itself and the next price update.

About the Company

Lupin Ltd. is a listed pharmaceuticals company in the healthcare sector, operating within the pharmaceuticals & drugs industry. The business has a market capitalisation of Rs 89,343.03 crore and remains one of the larger names in the segment. Its current valuation and profitability metrics are followed closely by investors because they help place the stock’s price behaviour in a broader fundamental context.

For those tracking Lupin company news, the present focus is not on a new business announcement but on the extended near-low pattern in the share price. That makes the stock relevant for readers scanning stocks in news today and stocks at one year low today. The company’s financial ratios, combined with the repeated price weakness, create the core of the present Lupin stock analysis.

Frequently Asked Questions

Why is Lupin trading near its 52-week low again?

Ans. The latest Univest data shows Lupin 52 Week Low Streak for a second straight session, but it does not confirm a company-specific reason. The repeated near-low pattern is clear, while the direct trigger remains unconfirmed from the latest Univest figures.

How long has Lupin stayed within 2% of its 52-week low?

Ans. Lupin has traded within 2% of its 52-week low for two consecutive sessions. That is why the current update is framed as Lupin 52 Week Low Streak rather than a one-day event.

What is Lupin share price today?

Ans. At 9:52 AM IST, Lupin share price was Rs 1,916.15, down Rs 40.85 or 2.09% from the previous close of Rs 1,957. The stock also touched a low of Rs 1,897.25 during trade.

How does Lupin look on valuation versus peers?

Ans. Lupin’s P/E of 16.19 is lower than the peer set shown here, including Aurobindo Pharma, Dr. Reddy’s, Cipla and Zydus Lifesciences. Its P/B of 3.76 is mid-range in that comparison.

What do Lupin’s ROE and ROCE show?

Ans. Lupin’s ROE of 27.11% and ROCE of 28.86% are both strong versus the industry medians supplied. These figures suggest solid capital efficiency even though the share price remains near a yearly low.

Is Lupin a 52 Week Low Stock right now?

Ans. The stock is trading within 2% of its 52-week low for a second straight session, so it fits the near-low pattern that readers often track under 52 Week Low Stocks. It is trading close to that level, not necessarily at.

What should investors monitor next in Lupin stock news?

Ans. Investors should watch whether Lupin can move away from the one-year low zone, along with the next share price update and any company or sector development that may influence sentiment. The current data confirms the pattern, not the cause.

Track Lupin Ltd. (LUPIN) Share Price on Univest

Use Lupin Ltd. (LUPIN) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.